Following embezzlement allegations and earlier sustained efforts to restructure its board, CTBC actively responded to engagement from EOS.
The company has since enhanced board effectiveness not only through improved structures and policies but with a robust and ongoing director training programme and board evaluation process, elevating investor confidence.
Case studies are shown to demonstrate engagement, EOS does not make any investment recommendations and the information is not an offer to buy or sell securities.
Dr Christine Chow
Lead: Asia & Emerging Markets. Sector lead: Technology
Dr Christine Chow is head of engagement in Asia and global emerging markets. She has 24 years’ experience working in the investment management industry, research and consulting. Christine's PhD thesis on shareholder engagement for responsible investment was short-listed for a UN award in Sweden for industry relevance and academic excellence. Christine is an elected member of the Court of governors at the London School of Economics (LSE) and a member of the School’s Investment Sub-Committee. She is a member of the Data Governance Task Force of the UK All Party Parliamentary Group on Artificial Intelligence and a board member of the International Corporate Governance Network (ICGN). In September 2019, she was named as one of Brummell Magazine’s Inspirational Women in the City of London. The list celebrates 30 female who are leaders in their respective fields, as chosen by an independent panel of industry professionals across the financial sector. Christine is a graduate of LSE and the University of Melbourne. She completed an executive education course on financial engineering at Stanford University.
NetEase published its inaugural ESG report in June 2020, covering material ESG topics including data privacy and protection, and GDPR compliance. EOS is pleased with its commitment to improve shareholder communication and continues to engage with the company on the wider ESG agenda.
HEINEKEN has improved the standard and transparency of its business conduct policies, increasing investor confidence. EOS continues to engage with the company on its accountability to its key values of integrity and fairness and on other ESG issues.
Takeda Pharmaceutical has significantly improved the transparency and accountability of its executive remuneration, aligning itself more closely to global peers. EOS has engaged it on this topic for the past 16 months to increase investor confidence in the company for the long term.